J&J taps into BARDA well a third time to speed up its PhIII Covid-19 vaccine trial

BARDA is pouring $454 million more into Johnson & Johnson’s Covid-19 vaccine efforts, as the pharma huffs and puffs to catch up with fast-moving frontrunners Pfizer/BioNTech and Moderna.